Scope Fluidics SA (SCP) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.102x

Based on the latest financial reports, Scope Fluidics SA (SCP) has a cash flow conversion efficiency ratio of -0.102x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-11.75 Million ≈ $-3.23 Million USD) by net assets (zł115.43 Million ≈ $31.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Scope Fluidics SA defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Scope Fluidics SA - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how Scope Fluidics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Scope Fluidics SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Scope Fluidics SA ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
51 TALK ONL. SP.ADR A 60
F:C4G0
N/A
Advenica AB
ST:ADVE
-0.104x
Precot Limited
NSE:PRECOT
0.013x
Royce Global Value Trust Inc
NYSE:RGT
0.001x
NEOWIZ HOLDINGS Corporation
KQ:042420
0.056x
Konfrut Gida Sanayi ve Ticaret AS
IS:KNFRT
0.015x
Tai Tung Communication Co Ltd
TW:8011
0.040x
Fortune Oriental Co Ltd
TW:2491
0.034x

Annual Cash Flow Conversion Efficiency for Scope Fluidics SA (2015–2024)

The table below shows the annual cash flow conversion efficiency of Scope Fluidics SA from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see SCP company net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 zł146.35 Million
≈ $40.28 Million
zł-25.10 Million
≈ $-6.91 Million
-0.172x +27.15%
2023-12-31 zł80.93 Million
≈ $22.27 Million
zł-19.06 Million
≈ $-5.24 Million
-0.235x -178.45%
2022-12-31 zł332.97 Million
≈ $91.64 Million
zł-28.16 Million
≈ $-7.75 Million
-0.085x +94.44%
2021-12-31 zł14.58 Million
≈ $4.01 Million
zł-22.19 Million
≈ $-6.11 Million
-1.522x -215.52%
2020-12-31 zł33.09 Million
≈ $9.11 Million
zł-15.96 Million
≈ $-4.39 Million
-0.482x +6.93%
2019-12-31 zł20.22 Million
≈ $5.56 Million
zł-10.48 Million
≈ $-2.88 Million
-0.518x -23.38%
2018-12-31 zł12.81 Million
≈ $3.52 Million
zł-5.38 Million
≈ $-1.48 Million
-0.420x -43.76%
2017-12-31 zł16.88 Million
≈ $4.64 Million
zł-4.93 Million
≈ $-1.36 Million
-0.292x +57.84%
2016-12-31 zł5.58 Million
≈ $1.53 Million
zł-3.87 Million
≈ $-1.06 Million
-0.693x -966.74%
2015-12-31 zł6.70 Million
≈ $1.84 Million
zł535.69K
≈ $147.43K
0.080x --

About Scope Fluidics SA

WAR:SCP Poland Diagnostics & Research
Market Cap
$92.58 Million
zł336.38 Million PLN
Market Cap Rank
#19576 Global
#154 in Poland
Share Price
zł123.40
Change (1 day)
-1.12%
52-Week Range
zł113.00 - zł180.80
All Time High
zł341.00
About

Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.